Proteins



Product Data Sheet

Siglec-15 Protein, Cynomolgus (HEK293, His)

Cat. No.: HY-P70743

Synonyms: Sialic acid-binding Ig-like lectin 15; Siglec-15; CD33 antigen-like 3; CD33L3

Species: Cynomolgus HEK293 Source:

Accession: A0A2K5UY47 (F20-T263)

Gene ID:

Molecular Weight: 30-40 kDa

PROPERTIES

AA Sec	quence
--------	--------

FVRTKIDTTE	NLLNTEVHSS	PAQRWSMQVP	AEVSAAAGDA
AVLPCTFTHP	HRHYDGPLTA	IWRAGEPYAG	PQVFRCAAAR
GSELCQTALS	LHGRFRLLGN	PRRNDLSLRV	ERLALADDRR
YFCRVEFAGD	VHDRYESRHG	VRLHVTAAPR	IINISVLPGP
AHAFRALCTA	EGEPPPALAW	SGPALGNGSA	AVPSSGQGHG
HLVTAELPAL	NHDGRYTCTA	ANSLGRSEAS	VYLFRFHGAS

GAST

Appearance

Lyophilized powder.

Formulation	Lyophilized from a 0.2 μm filtered solution of PBS, 150 mM NaCl, 0.3% Chaps, 5% Trehalose, pH 7.4

Endotoxin Level <1 EU/µg, determined by LAL method.

Reconsititution It is not recommended to reconstitute to a concentration less than 100 $\mu g/mL$ in ddH₂O.

Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

Siglec-15, a Siglec family member and type-1 transmembrane protein, is constitutively expressed in osteoclasts, macrophages and dendritic cells. Siglec-15 acts upstream of or within regulation of actin cytoskeleton organization. Siglec-15 deficiency can promote bone formation and reduce bone resorption, indicating that Siglec-15 plays a pivotal role in the development and differentiation of osteoclastogenesis and may serve as a target to inhibit bone resorption and promote bone remodeling that increases bone mass. Siglec-15 is a predominantly macrophage-mediated suppressor of T cell responses. In tumors, Siglec-15 is negatively regulated by IFN-y, thus influencing effector T cell-mediated antitumor

immunity. Genetic ablation or antibody blockade of Siglec-15 amplifies anti-tumor immunity in the TME and inhibits tumor growth in some mouse models. Siglec-15 as a potential target for normalization cancer immunotherapy $^{[1][2][3][4]}$.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com